PubMed Health⌕ Search

Biomedical subjects

M Bistrović

Publications and source records attributed to M Bistrović.

16 recordsLinked to original sources
PubMed1986

Combined treatment of 4'-epi-doxorubicin and radiation on hamster lung cells.

The purpose of this study was to test the type and the degree of cytotoxic effects of epirubicin and radiation in combined treatment on Chinese hamster lung cells in vitro. Experiments were performed with proliferating tissue culture cells. Cell kill was determined by colony-forming ability. The maximum killing effects were obtained when simultaneous action of drug treatment and irradiation occurred. Their interaction was synergistic. Synergism depended on time of drug incubation (epirubicin present for 1 h). Slight antagonism was noted after prolonged drug action (24 h).

Animals↗
PubMed1986

Combination of 4-epi-doxorubicin and irradiation--a new approach in the treatment of locoregionally advanced inoperable esophageal cancer.

The synergistic activity observed in vitro in V-79 hamster lung cells after treatment with 4-epi-doxorubicin (4-epi-DX) combined with irradiation stimulated a pilot study of 38 patients with inoperable locoregionally advanced squamous cell esophageal cancer. The patients (30 males, 8 females; mean age 60 years) had undergone no prior radiation or cytostatic drug therapy. Twenty tumors were localized in the middle third of the esophagus, and the remainder in the upper or lower third. Histological evidence of the tumor was obtained in all patients before treatment by endoscopy. The 33 evaluable cases included 30 squamous cell carcinomas, 2 anaplastic (squamous cell) carcinomas and 1 adenocarcinoma. The patients were irradiated in two opposite thoracic fields (Betatron-Siemens) with a total dosage of 3600-4000 cGy (200 cGy daily, 1000 weekly). The patients were concurrently administered 4-epi-DX at the dose of 50 mg/m2 i.v. daily on days 1, 2, 22 and 23; the total 4-epi-DX dosage was 200 mg/m2. The results showed that 4-epi-DX combined with irradiation had a pronounced antitumorigenic activity, since the 33 evaluable patients included 11 complete and 12 partial remissions, with a response rate of 70% (23/33). A minor regression (less than 50%) was observed in 6 cases, and progression of the disease in 4. The median duration of the remissions was 9 + months (14 + months in complete responders). In 8 patients with a complete clinical response even the endoscopic biopsy samples were negative. Toxicity was moderate and reversible, and mainly accounted for by radiation mucositis and retrosternal pain, alopecia and mild bone marrow suppression. Transient ECG changes were observed in 3 cases. The results of the pilot study show that the combination of 4-epi-DX and irradiation might constitute successful palliative treatment for squamous cell esophageal cancer.

Adenocarcinoma↗
PubMed1986

RBE of 20 kV and 70 kV X-rays determined for survival of V 79 cells.

The survival curves of V 79 cells were compared for various types of sparsely ionizing radiation: 20 kV, 70 kV and 42 MV X-rays, 60Co gamma-rays and 40 MeV electrons. A carefully calibrated thin window chamber was used for accurate dosimetry. The survival curves for cells exposed to 20 kV X-rays and 70 kV X-rays differed from that for 60Co gamma-rays only by a dose-scaling factor t(RBE). RBE with respect to 60Co gamma-rays could then be considered as dose-independent: 1.19 +/- 0.06 for 70 kV X-rays and 1.40 +/- 0.07 for 20 kV X-rays. RBE of 42 MV X-rays and 40 MeV electrons was not significantly different from 1.

Animals↗
PubMed1983

Localization of radioactive sources by radiotherapy simulator and application to gynaecology.

During a short-lasting high radioactivity gynaecological treatment the position of the sources does not change significantly. A fast and accurate technique was developed allowing for the determination of source positions. It is based on the use of a radiotherapy simulator. The simulator was declined by 20 degrees to the right, and the X-ray projection of the sources was copied with blue colour on a PVC foil firmly attached to the intensifier display. This was repeated with the simulator declined by 20 degrees to the left and with red. From the paralax shift the three dimensional position of sources was evaluated, and dose distribution was then calculated using a computer program.

Computers↗
PubMed1976

Interaction of bleomycin and radiation in combined treatment on mouse L cells.

Using an established line of L cells, we studied survival properties and recovery after combined action of bleomycin and radiation. A moderate synergistic effect was observed when bleomycin and radiation were given simultaneously. Cell recovery from radiation damage was not affected by bleomycin. Results seem to be in agreement with previously published data.

Animals↗
PubMed1976

The energy response of LiF, film and a chemical dosemeter to high energy photons and electrons.

The physical responses of LiF, film and a chemical dosemeter in high energy photon and electron beams has been studied. It is shown that the response for film and the chemical dosemeter does not change significantly up to 42 MeV, while for LiF it decreases by about 10%. Analysis of calculations and measurements showed that this decrease could not be explained by existing theories.

Electrons↗
PubMedDate not supplied

[Radiotherapy treatment of lymphoma].

Radiotherapy and/or chemotherapy are primary treatment modalities in the therapy of lymphoma. The treatment depends on the lymphoma type, stage of disease and patients general condition. Radiation therapy is applied with curative or palliative intent, either as a single or combined modality treatment. In patients with stage I and stage IIA Hodgkin's lymphoma (HL) and no adverse risk factors, radiotherapy is applied as a single modality treatment. Moreover, treatment modalities in early-stage HL (I and IIA) consisting of either chemotherapy alone or combined with radiotherapy are the subject of ongoing clinical trials. In addition to the region/s with clinically involved lymph nodes, the target volume of radiation therapy applied as a primary radical treatment modality (stages I and IIA) also includes non-involved lymph nodes of adjacent regions aimed at their prophylactic irradiation. Such extended radiation fields are, for instance, the "mantle-field" and the "inverted-Y" field. On the other hand, with radiation therapy applied in combination with chemotherapy, the target volume depends on both the stage of the disease and the number of chemotherapy cycles. Likewise, the combined treatment is dependent on whether the role of radiotherapy is only the control of clinically involved regions, or of regions with potential subclinical disease too. Chemotherapy is the most frequently applied treatment modality in the management of non-Hodgkin's lymphoma (NHL). Radiation therapy as a single modality treatment with curative intent is applied in patients with, according to the histopathologic classification of the disease, the indolent NHL type and pathological stages I and II in continuation. The target radiation volume includes the clinically involved region, and possibly other adjacent clinically non-involved regions. In higher stages of disease or other, more aggressive NHL chemotherapy is applied either alone or in combination with adjuvant radiotherapy.

Hodgkin Disease↗